Ruud Smits
NautaDutilhThe group at NautaDutilh displays vast expertise in handling a broad array of corporate matters for its varied client list, including seed rounds, share offerings, and private placement financings. Practice co-head Ruud Smits has a great deal of transactional expertise within the healthcare and life sciences space, advising start-ups and investors on M&A and VC-backed financing rounds. Co-head Jeroen Boelens is an IP specialist who focuses on technology within the pharma and biotech spaces, frequently assisting clients with biotech IPOs and licensing M&A. Anne Marie Verschuur departed the practice in May 2023.
Legal 500 Editorial commentary
Testimonials
Collated independently by Legal 500 research team.
- 'Ruud Smits is extremely engaged and knowledgeable about the sector. He is able to negotiate in a very businesslike manager which manages complex cross-cultural situations perfectly.'
- 'NautaDutilh's team is highly professional and pragmatic. They understand the client need and do not just use cookie-cutter approaches.'
Key clients
- Forbion
- NewAmsterdam Pharma
- Pharvaris
- GSK
- Rhythm Pharmaceutcials
- Avania
- Ginkgo
- The Protein Brewery
- Lumicks
- Mimetas
- Pharmathen
- Galenicum
Work highlights
- Advised Synaffix on its sale to Lonza Group AG for up to $160m.
- Advised NewAmsterdam Pharma on its upsized Secondary Offering of Ordinary Shares and its $726m business combination with Frazier Lifesciences Acquisition Corp.
- Advised Neogene Therapeutics on its sale to AstraZeneca for up to €320m.
Lawyers
Leading partners
The strongest partners in their field, leading on market-leading deals and endorsed by peers and clients alike.
Practice head
The lawyer(s) leading their teams.
Ruud Smits, Jeroen Boelens